A kind of developing biodegradable medical polyurethane foam and preparation method thereof

Through the development of biodegradable medical polyurethane foam, the existing materials are solved, and the polyurethane foam with high support strength and development function is achieved. It is suitable for cardiovascular sealing and filling, ensuring the safety of the material and development effect.

CN118652466BActive Publication Date: 2024-11-12SICHUAN UNIV

Patent Information

Application Number
CN202411132779.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-08-19
Publication Date
2024-11-12
Estimated Expiration
2044-08-19

AI Technical Summary

Technical Problem

The existing medical embolization materials have problems such as poor density, insufficient support strength, difficulty in developing and difficult degradation control when treating abdominal aortic aneurysms, especially in the treatment of hypertension, which is difficult to meet the requirements of long-term development and safe implantation.

Method used

The preparation method of developing biodegradable medical polyurethane foam is adopted to form polyurethane microspheres with core-shell structures through a two-step polymerization and foaming process, and the development function and biodegradability of the material are ensured by blending the developer and inorganic particles.

Benefits of technology

It has achieved high density and high support strength developing polyurethane foam, which can develop and track in blood vessels, quickly form thrombus and degrade in the body, and is non-toxic and metabolized. It is suitable for cardiovascular blocking and filling materials.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118652466B_ABST
    Figure CN118652466B_ABST
Patent Text Reader

Abstract

The invention discloses a developing biodegradable medical polyurethane foam and a preparation method thereof, and relates to the technical field of preparation of medical embolic materials. The method comprises the following steps: mixing the developing material and isocyanate evenly, then adding polyol and catalyst, stirring evenly, then adding dispersant and water, stirring to form a stable suspension system; gradually heating up for polymerization to obtain developing polyurethane microspheres; mixing microspheres, isocyanate and part of polyol, stirring for prepolymerization, then adding the remaining polyol, catalyst, silicone oil, foaming agent and water, polymerizing and foaming the obtained mixture and heat treating, making holes, and obtaining developing biodegradable medical polyurethane foam. The foam material of the invention can be developed, blocked and degraded in minimally invasive intervention, achieving the purpose of intraoperative confirmation, postoperative tracking and prognostic diagnosis, and is suitable for cardiovascular blocking filling materials. The problem of poor performance of embolic materials in the prior art is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of preparation of medical embolic materials, and in particular to a developable biodegradable medical polyurethane foam and a preparation method thereof. Background Art

[0002] In the process of treating abdominal aortic aneurysm, postoperative endoleak complications often occur. Therefore, minimally invasive interventional embolization is usually chosen to reduce the blood flow rate and circulation volume so that thrombosis can be successfully completed in the aneurysm cavity. Commonly used embolic materials include spring coils, gelatin powder, tissue adhesives, thrombin and vascular plugs. Although the above materials currently have basic clinical examples, there are still some shortcomings. Metal spring coils are currently the most commonly used vascular embolization materials. They have long-term stability and strong supporting performance. The disadvantage of the spring coils is that after intervention, the anchoring area and the stent cannot be completely fitted with the aortic wall, and the density is poor, which may lead to incomplete embolization and complications such as endoleak. Data show that the thrombosis rate of metal spring coils is between 80-92%. Long-term implantation will also lead to the precipitation of metal ions, which may cause allergies, inflammation, etc., and after achieving the medical function, another surgery is required to remove the formed thrombus; gelatin and thrombin are mainly used in short-term embolization. The advantages are fast thrombosis, no toxic side effects and short metabolism time, which minimizes the prognosis and side effects. The disadvantage is that they cannot provide high support strength. High blood pressure can easily cause embolism to enter the systemic circulation and affect other tissues or structures. The degradation rate is too fast and it is difficult to control the embolization function. Therefore, it does not meet the thrombosis conditions of arteries with fast flow rate and high blood pressure.

[0003] At the same time, because the implanted foam is a polymer material, which is mainly composed of a hydrocarbon structure and hardly develops under X-rays, it is impossible to judge the real state of the material after implantation and whether it plays a medical role. Therefore, a developer is introduced to develop the material after implantation. The developer prepared by a simple blending method is actively released because there is no chemical bonding, and the degradable material will also accelerate the release rate. Once the release is completed, the later development function is lost. Considering the active release of the developer and the dispersibility of the material in the substrate, the addition ratio of the developer is usually high, even exceeding 50%. If the copolymerization method is directly used, the iodine compound is highly reactive and easily chemically reacted and becomes ineffective, and the development function will also be lost. At the same time, copolymerization will also cause the physical properties of the foam to decrease. The products currently available on the market are hydrogel microspheres. This type of embolization product has a short timeliness and cannot be implanted for long-term development observation.

[0004] Therefore, developing an embolic material with high density, high support strength, controllable degradation cycle and imaging will become a trend in the future. Summary of the invention

[0005] In order to solve the above technical problems, the purpose of the present invention is to provide a developable biodegradable medical polyurethane foam and a preparation method thereof, so as to solve the problem of poor performance of embolic materials in the prior art.

[0006] The technical solution of the present invention to solve the above technical problems is as follows: Provide a developable biodegradable medical polyurethane foam and a preparation method thereof, comprising the following steps:

[0007] (1) Mix the developer material and isocyanate evenly, then add the polyol and catalyst, stir evenly, then add the dispersant and water, and stir to form a stable suspension system;

[0008] (2) polymerizing the suspension system obtained in step (1) for the first time, then polymerizing it for the second time, cooling it, centrifuging it, washing it and drying it to obtain developed polyurethane microspheres;

[0009] (3) mixing the developed polyurethane microspheres obtained in step (2), isocyanate and part of the polyol, stirring for prepolymerization, then adding the remaining polyol, catalyst, silicone oil, foaming agent and water, polymerizing and foaming the obtained mixture and heat treating it to obtain an intermediate;

[0010] (4) The intermediate obtained in step (3) is soaked in a pore-forming agent to form pores, and then washed and dried to obtain a developable biodegradable medical polyurethane foam.

[0011] On the basis of the above technical solution, the present invention can also be improved as follows:

[0012] Furthermore, in step (1), the mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 1-30:5-70:5-70:0.1-5:0.2-2:100.

[0013] The beneficial effect of adopting the above further technical solution is that the above ratio can form stable cross-linked polyurethane microspheres containing developing materials, and the developing strength can be controlled by changing the ratio.

[0014] Furthermore, in step (1), the mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 8:55:27:1.8:1.5:100.

[0015] Furthermore, in step (1), the developing material is tantalum nanoparticles, bismuth basic carbonate, bismuth oxychloride, bismuth oxide, barium sulfate or tungsten.

[0016] Furthermore, in step (1), the isocyanate is at least one of hexamethylene diisocyanate, trimethyl hexamethylene diisocyanate, isophorone diisocyanate, hydrogenated xylylene diisocyanate, ethyl lysine diisocyanate, toluene diisocyanate and methylene diphenyl diisocyanate.

[0017] Furthermore, in step (1), the polyol is at least one of polycaprolactone diol, polylactic acid diol, polyglycolic acid diol, polycaprolactone triol, polylactic acid triol, polyglycolic acid triol, polycaprolactone tetraol, polylactic acid tetraol, polyglycolic acid tetraol, polycarbonate diol, polyethylene glycol, polytetrahydrofuran diol, polyhexamethylene ether diol, butanediol, propylene glycol, triethanolamine, hydroxypropyl ethylenediamine, glycerol, pentaerythritol, trimethylolethane and tris(hydroxymethyl)aminomethane.

[0018] Furthermore, in step (1), the catalyst is an organic metal catalyst.

[0019] Furthermore, in step (1), the catalyst is an organotin catalyst or an organobismuth catalyst.

[0020] Furthermore, the organotin catalyst is at least one of stannous octoate, dibutyltin dilaurate, dibutyltin diacetate and dibutyltin didodecylsulfide.

[0021] Furthermore, the organic bismuth catalyst is at least one of bismuth laurate, bismuth isooctanoate and bismuth neodecanoate.

[0022] Furthermore, in step (1), the dispersant is at least one of cellulose, polyvinyl pyrrolidone, polyvinyl alcohol and hydroxy-modified cellulose.

[0023] Furthermore, in step (1), the stirring speed when forming a stable suspension system is 500-2000 rpm.

[0024] Furthermore, in step (2), the polymerization is carried out at 40-60° C. for 2.5-3.5 hours to complete the first polymerization process.

[0025] Furthermore, in step (2), polymerization is carried out at 50° C. for 3 hours to complete the first polymerization process.

[0026] Furthermore, in step (2), the polymerization is carried out at 75-85° C. for 7-9 hours to complete the second polymerization process.

[0027] Furthermore, in step (2), polymerization is carried out at 80° C. for 8 hours to complete the second polymerization process.

[0028] Furthermore, in step (2), centrifugation and washing are repeated, and then drying is performed.

[0029] Furthermore, in step (3), the mass ratio of the developed polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 1-30:30-80:10-80:0.1-5:1-15:0.1-15:0.5-5.

[0030] Furthermore, in step (3), the mass ratio of the developed polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 10:40:42:1.3:4.1:0.3:2.3.

[0031] Furthermore, in step (3), the mass ratio of the partial polyol to the remaining polyol is 70:30.

[0032] Furthermore, in step (3), the isocyanate is at least one of hexamethylene diisocyanate, trimethyl hexamethylene diisocyanate, isophorone diisocyanate, hydrogenated xylylene diisocyanate, ethyl lysine diisocyanate, toluene diisocyanate and methylene diphenyl diisocyanate.

[0033] Furthermore, in step (3), the polyol is at least one of polycaprolactone diol, polylactic acid diol, polyglycolic acid diol, polycaprolactone triol, polylactic acid triol, polyglycolic acid triol, polycaprolactone tetraol, polylactic acid tetraol, polyglycolic acid tetraol, polycarbonate diol, polyethylene glycol, polytetrahydrofuran diol, polyhexamethylene ether diol, butanediol, propylene glycol, triethanolamine, hydroxypropyl ethylenediamine, glycerol, pentaerythritol, trimethylolethane and tris(hydroxymethyl)aminomethane.

[0034] Furthermore, in step (3), the catalyst is an organic metal catalyst.

[0035] Furthermore, in step (3), the catalyst is an organotin catalyst or an organobismuth catalyst.

[0036] Furthermore, the organotin catalyst is at least one of stannous octoate, dibutyltin dilaurate, dibutyltin diacetate and dibutyltin didodecylsulfide.

[0037] Furthermore, the organic bismuth catalyst is at least one of bismuth laurate, bismuth isooctanoate and bismuth neodecanoate.

[0038] Furthermore, in step (3), the foaming agent is at least one of dichloromethane, chloroform and acetone.

[0039] Furthermore, in step (3), the prepolymerization is carried out by stirring for 24 hours.

[0040] Furthermore, in step (3), the prepolymerization is carried out by stirring for 22-26 hours.

[0041] Furthermore, in step (3), the polymerization and foaming are carried out at 75-85°C for 7.5-8.5 hours and the heat treatment is carried out for 1.8-2.2 days.

[0042] Furthermore, in step (3), the polymerization and foaming are carried out at 80° C. for 8 h and the heat treatment is carried out for 2 d.

[0043] Furthermore, in step (4), the pore-forming agent is a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:4-6:3-5.

[0044] Furthermore, in step (4), the pore-forming agent is a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:5:4.

[0045] Furthermore, in step (4), the extrusion and soaking are performed for 4-6 minutes to complete the hole making process.

[0046] Further, in step (4), the mixture is squeezed and soaked for 5 minutes.

[0047] The invention also provides a developable biodegradable medical polyurethane foam, which is prepared by the method.

[0048] The present invention also provides application of the above-mentioned developable biodegradable medical polyurethane foam in the preparation of vascular embolization materials.

[0049] The present invention has the following beneficial effects:

[0050] 1. The present invention prepares a developer and polyurethane into polyurethane developing microspheres with a core-shell structure, and then adds the microspheres to a polyurethane prepolymer, and co-foams to prepare a polyurethane foam material with a developing function. The foam material of the present invention can be developed and tracked in minimally invasive intervention to confirm whether the material has reached the target position, can quickly form a thrombus after implantation to complete the blocking effect, can continuously develop to reflect the true state and blocking effect of the material, and facilitates the review of the prognosis. It is then degraded and metabolized by the body without toxicity, achieving the purpose of intraoperative confirmation, postoperative tracking, and prognosis diagnosis, and is suitable for cardiovascular blocking filling materials.

[0051] 2. The present invention utilizes polymer microspheres to wrap inorganic particles, and in-situ blending, and effectively avoids the influence of inorganic particles on polyurethane foaming, including density, pore size and porosity, through a two-step method, thereby minimizing the influence on the self-expansion performance of the foam.

[0052] 3. The method of the present invention is also applicable to other examples of using polymer materials as implants instead of metals, and the imaging agent can be replaced according to the implantation site and purpose. BRIEF DESCRIPTION OF THE DRAWINGS

[0053] Figure 1 The polyurethane foam prepared in Example 1;

[0054] Figure 2 The non-developable polyurethane foam of Comparative Example 1;

[0055] Figure 3 The developed polyurethane foam of Comparative Example 2;

[0056] Figure 4 This is the visibility of the polyurethane foam prepared in Example 1 under X-ray. DETAILED DESCRIPTION

[0057] The principles and features of the present invention are described below in conjunction with the accompanying drawings. The examples are only used to explain the present invention and are not used to limit the scope of the present invention. If specific conditions are not specified in the embodiments, they are carried out according to normal conditions or conditions recommended by the manufacturer. If the manufacturer is not specified for the reagents or instruments used, they are all conventional products that can be purchased commercially.

[0058] Embodiment 1:

[0059] A developable biodegradable medical polyurethane foam, the preparation method of which comprises the following steps:

[0060] (1) Mix the developer (tantalum nanoparticles) and isocyanate (hexamethylene diisocyanate) evenly, then add polyol (lactic acid triol and triethanolamine in a mass ratio of 25:2) and catalyst (stannous octoate), stir evenly, then add dispersant (cellulose) and water, and stir at a high speed of 1000 rpm to form a stable suspension system;

[0061] The mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 8:55:27:1.8:1.5:100;

[0062] (2) polymerizing the suspension system obtained in step (1) at 50° C. for 3 h for the first time and at 80° C. for the second time for 8 h, cooling, centrifuging and separating the solid phase to obtain a solid phase, washing, repeating the centrifugation and washing, and vacuum drying the obtained solid phase to obtain developed polyurethane microspheres;

[0063] (3) The developed polyurethane microspheres prepared in step (2), isocyanate (hexamethylene diisocyanate) and part of the polyol (lactic acid triol and triethanolamine in a mass ratio of 40:2) are mixed and stirred for 24 hours for prepolymerization, and then the remaining polyol (the mass ratio of part of the polyol to the remaining polyol is 70:30), catalyst (bismuth laurate), silicone oil, foaming agent (dichloromethane) and water are quickly added, and after mixing, the mixture is transferred to an oven at 80°C for polymerization and foaming for 8 hours, and the heat treatment is continued for 2 days to obtain an intermediate;

[0064] The mass ratio of the developing polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 10:40:42:1.3:4.1:0.3:2.3;

[0065] (4) The intermediate obtained in step (3) is squeezed and soaked in a pore-forming agent (a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:5:4) for 5 minutes to form pores, and then washed with water, isopropanol and deionized water in sequence, and dried to obtain a developable biodegradable medical polyurethane foam.

[0066] Embodiment 2:

[0067] A developable biodegradable medical polyurethane foam, the preparation method of which comprises the following steps:

[0068] (1) Mix the developer (bismuth basic carbonate) and isocyanate (trimethylhexamethylene diisocyanate) evenly, then add the polyol (polycaprolactone diol) and catalyst (bismuth neodecanoate), stir evenly, then add the dispersant (cellulose) and water, and stir at 500 rpm to form a stable suspension system;

[0069] The mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 1:5:5:0.1:0.2:100;

[0070] (2) polymerizing the suspension system obtained in step (1) at 60° C. for a first time for 2.5 h and at 85° C. for a second time for 7 h, cooling, centrifuging and separating the solid phase to obtain a solid phase, washing, repeating the centrifugation and washing, and vacuum drying the obtained solid phase to obtain developed polyurethane microspheres;

[0071] (3) The developed polyurethane microspheres prepared in step (2), isocyanate (trimethylhexamethylene diisocyanate) and part of the polyol (polycaprolactone diol) are mixed and stirred for 22 hours for prepolymerization, and then the remaining polyol (the mass ratio of the part of the polyol to the remaining polyol is 70:30), catalyst (dibutyltin dilaurate), silicone oil, foaming agent (dichloromethane) and water are quickly added, and after mixing, the mixture is transferred to a 75°C oven for polymerization and foaming for 8.5 hours, and the heat treatment is continued for 2.2 days to obtain an intermediate;

[0072] The mass ratio of the developing polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 1:30:10:0.1:1:0.1:0.5;

[0073] (4) The intermediate obtained in step (3) is squeezed and soaked in a pore-forming agent (a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:4:3) for 4 minutes to form pores, and then washed with water, isopropanol and deionized water in sequence, and dried to obtain a developable biodegradable medical polyurethane foam.

[0074] Embodiment 3:

[0075] A developable biodegradable medical polyurethane foam, the preparation method of which comprises the following steps:

[0076] (1) Mix the developer (bismuth oxychloride) and isocyanate (methylene diphenyl diisocyanate) evenly, then add the polyol (polyethylene glycol) and the catalyst (dibutyltin(didodecylsulfide)), stir evenly, then add the dispersant (cellulose) and water, and stir at a high speed of 2000 rpm to form a stable suspension system;

[0077] The mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 30:70:70:5:2:100;

[0078] (2) polymerizing the suspension system obtained in step (1) at 50° C. for 3 h for the first time and at 80° C. for the second time for 8 h, cooling, centrifuging and separating the solid phase to obtain a solid phase, washing, repeating the centrifugation and washing, and vacuum drying the obtained solid phase to obtain developed polyurethane microspheres;

[0079] (3) The developed polyurethane microspheres prepared in step (2), isocyanate (methylene diphenyl diisocyanate) and part of the polyol (polyethylene glycol) are mixed and stirred for 26 hours for prepolymerization, and then the remaining polyol (the mass ratio of the part of the polyol to the remaining polyol is 70:30), catalyst (dibutyltin diacetate), silicone oil, foaming agent (dichloromethane) and water are quickly added, and after mixing, the mixture is transferred to an oven at 85°C for polymerization and foaming for 7.5 hours, and the heat treatment is continued for 1.8 days to obtain an intermediate;

[0080] The mass ratio of the developing polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 30:80:80:5:15:15:5;

[0081] (4) The intermediate obtained in step (3) is squeezed and soaked in a pore-forming agent (a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:6:5) for 6 minutes to form pores, and then washed with water, isopropanol and deionized water in sequence, and dried to obtain a developable biodegradable medical polyurethane foam.

[0082] Comparative Example 1:

[0083] A non-developable biodegradable medical polyurethane foam, the preparation method of which comprises the following steps:

[0084] Steps (1) and (2) are not included, and developing microspheres are not added in step (3). The rest is the same as in Example 1.

[0085] Comparative Example 2:

[0086] A developable biodegradable medical polyurethane foam, the preparation method of which comprises the following steps:

[0087] Without steps (1) and (2), the developer material is directly added to step (3) to prepare the foam, and the rest is the same as in Example 1.

[0088] Test example

[0089] 1. The polyurethane foams of Example 1 and Comparative Examples 1-2 were subjected to ETM testing. The results are shown in Figure 1-3 .

[0090] Depend on Figure 1-3 It can be seen that the pore size and distribution of the polyurethane foam with developing microspheres added in the present invention are basically consistent with those of the non-developing polyurethane foam in comparative example 1, while the pore size distribution of the polyurethane foam with inorganic particles directly added in comparative example 2 is uneven and the pore size is significantly reduced.

[0091] 2. The polyurethane foam prepared in Example 1 was developed and tested under X-ray, and the specific testing method was Micro-CT. Figure 4 .

[0092] Depend on Figure 4 It can be seen that the polyurethane foam of the present application has X-ray visibility.

[0093] 3. The performance of the polyurethane foams of Example 1 and Comparative Examples 1-2 was tested. The results are shown in Table 1.

[0094] Table 1 Performance parameters

[0095]

[0096] As can be seen from Table 1, after adding the developer microspheres in the present invention, the pore size and mechanical properties of the foam are similar to those of the non-developer foam prepared by the one-step method in Comparative Example 1, indicating that the developer microspheres in the present invention will not significantly cause the performance loss of the foam; while in Comparative Example 2, directly adding the inorganic developer material will affect the foaming process, seriously leading to uneven pore size distribution of the foam, and having a significant impact on the foam density and mechanics, limiting the application of the foam.

[0097] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. A method for preparing a biodegradable medical polyurethane foam, characterized in that: The following steps are involved: (1) Mix the developer material and isocyanate evenly, then add the polyol and catalyst, stir evenly, then add the dispersant and water, and stir to form a stable suspension system; (2) polymerizing the suspension system obtained in step (1) for the first time, then polymerizing it for the second time, cooling it, centrifuging it, washing it and drying it to obtain developed polyurethane microspheres; (3) mixing the developed polyurethane microspheres obtained in step (2), isocyanate and part of the polyol, stirring for prepolymerization, then adding the remaining polyol, catalyst, silicone oil, foaming agent and water, polymerizing and foaming the obtained mixture and heat treating it to obtain an intermediate; (4) soaking the intermediate obtained in step (3) in a pore-forming agent to form pores, and then washing and drying to obtain a developable biodegradable medical polyurethane foam; In step (1), the developing material is tantalum nanoparticles, bismuth basic carbonate, bismuth oxychloride, bismuth oxide, barium sulfate or tungsten; In step (3), the foaming agent is at least one of dichloromethane, chloroform and acetone; In step (3), the polymerization and foaming are carried out at 75-85°C for 7.5-8.5 hours and the heat treatment is carried out for 1.8-2.2 days; In step (4), the pore-forming agent is a mixture of sodium hydroxide, isopropanol and water in a volume ratio of 1:4-6:3-5.

2. The method for preparing the developable biodegradable medical polyurethane foam according to claim 1, characterized in that: In step (1), the mass ratio of the developing material, isocyanate, polyol, catalyst, dispersant and water is 1-30:5-70:5-70:0.1-5:0.2-2:

100.

3. The method for preparing the developable biodegradable medical polyurethane foam according to claim 1, characterized in that: In step (2), the polymerization is carried out at 40-60° C. for 2.5-3.5 hours to complete the first polymerization process.

4. The method for preparing the developable biodegradable medical polyurethane foam according to claim 1, characterized in that: In step (2), the polymerization is carried out at 75-85° C. for 7-9 hours to complete the second polymerization process.

5. The method for preparing the developable biodegradable medical polyurethane foam according to claim 1, characterized in that: In step (3), the mass ratio of the developed polyurethane microspheres, isocyanate, polyol, catalyst, silicone oil, foaming agent and water is 1-30:30-80:10-80:0.1-5:1-15:0.1-15:0.5-5.

6. A developed biodegradable medical polyurethane foam, characterized in that: The polyurethane foam is prepared by the method for preparing the developable biodegradable medical polyurethane foam according to any one of claims 1 to 5.

7. Use of the developable biodegradable medical polyurethane foam according to claim 6 in the preparation of vascular embolization materials.

Citation Information

Patent Citations

  • Vascular prosthesis for leak prevention during endovascular aneurysm repair

    CN110612072A

  • Low-density high-porosity polyurethane foam material and preparation method thereof

    CN116656002A

  • Core / shell type polyurethane magnetic compound microsphere, preparation method and use thereof

    CN1966097A

  • Solid oil-in-water emulsion for use in make-up products for skin, mucous membranes and-or keratin fibers, comprises aqueous phase containing gellane, at least one oil, and surfactant system

    FR2794997A1

  • In-Situ Forming Foams for Treatment of Aneurysms

    US20120265287A1

Cited By

  • Polyurethane multi-part kit system

    US12617890B2